B-244 is under clinical development by AOBiome and currently in Phase III for Acne Vulgaris. According to GlobalData, Phase III drugs for Acne Vulgaris have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how B-244’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
B-244 is under development for the treatment of acne vulgaris, hypertension, atopic dermatitis, rosacea, migraine, pruritis, seasonal allergic rhinitis, pulmonary diseases and gut disorders. The drug candidate is administered by topical, nasal routes. It comprises of single strain of ammonia-oxidizing bacteria (AOB) Nitrosomonas eutropha D23. AOB are ubiquitous bacteria that lack pathogenic potential and restore natural NO levels of the skin by stabilizing the NO-dependent signaling pathways. It was also under development for the treatment of chronic wounds.
AOBiome is a clinical-stage therapeutics company. The company develops topical biologics for the treatment of inflammatory skin conditions. It is undergoing clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea. AOBiome is headquartered in the US.
For a complete picture of B-244’s drug-specific PTSR and LoA scores, buy the report here.